The Children's Hospital of Pittsburgh (CHP) is the pediatric arm of the Pittsburgh Cancer Institute (PCI). The pediatric cancer center for Western PA., Eastern Ohio, and Northern W.Va., and an active member of the Children's Cancer Study Group (CCSG) since 1961. Our multidisciplinary pediatric oncology team includes 7 oncologists, 5 surgeons (including neuro and orthopedic), radiation oncologists, diagnostic radiologists, tumor pathologists, a hematopathologist, a cytogeneticist, a neurologist, an epidemiologist, a cardiologist, a developing bone marrow transplant program plus psychology and psychiatric liaison and a complete support team (Nursing, data managers, social service. etc.). Our primary aim is to increase scientific contributions to CCSG through expansion of our laboratory and clinical research base, increased committee involvement, and maximum participation in CCSG studies with emphasis on increasing participation in biologic and epidemiologic studies as well as full participation in therapeutic studies. We presently enter 93 patients per year on CCSG studies with an increasing number of biologic specimens provided. Among the scientific contributions to CCSG during the current grant periods were: discovering a malignant brain tumor rate 226 times the expected for children """"""""cured"""""""" of ALL on CCG-141, osteogenic sarcoma survival is significantly improved if 50% or greater tumor cells are necrosed following preoperative chemotherapy; medulobastomas can be separated into prognostic groups to permit meaningful studies. The addition of Neurology, Epidemiology, Cytogenetics, and Bone Marrow Transplant to our oncology team en- ables us to increase our scientific contributions and leadership to benefit CCSG immediately. Non-CCSG laboratory and clinical cancer research now underway by members of our team will benefit CCSG in the future: The inter-action of hormonal growth factors with cancer cells; identification of histochemical and immunologic markers for a variety of solid tumors; flow cytometry and ALL-ANLL monoclonal antibodies; chromosome fragility (breakage) in leukemia bone marrow cells and their relationship to the oncogenic process; neurochemical approaches to the therapy of neuroblastoma; clinically, as apart of the PA. Pediatric Oncology Network, we surveyed long term cancer survivors to document the late effects of therapy on growth and development, and on neuropsychologic function. Planned are Phase I investigations with PCI of biologic modifiers (II-2) in the treatment of pediatric malignancies. The now open, new CHP physical plant with increased oncology research space will help to fulfil our primary aim.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA036015-07
Application #
3557880
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1984-02-01
Project End
1993-11-30
Budget Start
1989-12-01
Budget End
1990-11-30
Support Year
7
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Children's Hosp Pittsburgh/Upmc Health Sys
Department
Type
DUNS #
044304145
City
Pittsburgh
State
PA
Country
United States
Zip Code
15224
Neudorf, Steven; Sanders, Jean; Kobrinsky, Nathan et al. (2004) Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood 103:3655-61
Shamberger, Robert C; LaQuaglia, Michael P; Gebhardt, Mark C et al. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 238:563-7; discussion 567-8
Davies, Stella M; Bhatia, Smita; Ross, Julie A et al. (2002) Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 100:67-71
Wells, Robert J; Reid, Joel M; Ames, Matthew M et al. (2002) Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942. J Pediatr Hematol Oncol 24:89-93
Lange, Beverly J; Bostrom, Bruce C; Cherlow, Joel M et al. (2002) Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99:825-33
Ou, Shu Xiao; Han, Dehui; Severson, Richard K et al. (2002) Birth characteristics, maternal reproductive history, hormone use during pregnancy, and risk of childhood acute lymphocytic leukemia by immunophenotype (United States). Cancer Causes Control 13:15-25
Wells, R J; Arthur, D C; Srivastava, A et al. (2002) Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. Leukemia 16:601-7
Arndt, C A; Krailo, M D; Liu-Mares, W et al. (2001) Phase I study of CI-958 in children and adolescents with recurrent solid tumors. Cancer 91:1166-9
Adamson, P C; Widemann, B C; Reaman, G H et al. (2001) A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group study. Clin Cancer Res 7:3034-9
Cooper, R; Khakoo, Y; Matthay, K K et al. (2001) Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group. Med Pediatr Oncol 36:623-9

Showing the most recent 10 out of 14 publications